Skip to main content
SpringerLink
Log in

Risks and benefits of discontinuing statins in advanced illness

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2012 US dollars

References

  1. Kutner JS, et al. Safety and Benefit of Discontinuing Statin Therapy in the Setting of Advanced, Life-Limiting Illness: A Randomized Clinical Trial. JAMA Internal Medicine : 23 Mar 2015. Available from: URL: http://doi.org/10.1001/jamainternmed.2015.0289.

  2. Holmes HM, et al. Evidence-Based Deprescribing of Statins in Patients With Advanced Illness. JAMA Internal Medicine : 23 Mar 2015. Available from: URL: http://archinte.jamanetwork.com/article.aspx?articleid=2204031.

  3. Scott IA, et al. Reducing Inappropriate Polypharmacy -- The Process of Deprescribing. JAMA Internal Medicine : 23 Mar 2015. Available from: URL: http://archinte.jamanetwork.com/article.aspx?articleid=2204035.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Risks and benefits of discontinuing statins in advanced illness. Reactions Weekly 1545, 11 (2015). https://doi.org/10.1007/s40278-015-9102-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-015-9102-6

Search

Navigation